Vivos Therapeutics (VVOS) EBITDA (2020 - 2026)

Vivos Therapeutics (VVOS) has reported EBITDA for 7 consecutive years, with -$4.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 0.88% year-over-year to -$4.5 million in Q2 2026; TTM through Jun 2026 was -$21.8 million, a 60.75% decrease from a year earlier, with the FY2025 full-year figure at -$19.2 million, down 79.87% from the prior year.
• EBITDA was -$4.5 million for Q2 2026 at Vivos Therapeutics, up from -$6.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.8 million in Q2 2024 and troughed at -$6.8 million in Q2 2022.
• A 5-year average of -$4.5 million and a median of -$4.5 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 58.43% in 2024 and slumped 148.64% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$5.8 million in 2022, then soared by 31.75% to -$3.9 million in 2023, then surged by 31.2% to -$2.7 million in 2024, then tumbled by 143.24% to -$6.6 million in 2025, then jumped by 31.25% to -$4.5 million in 2026.
• The last three EBITDA figures came in at -$4.5 million (Q2 2026), -$6.3 million (Q1 2026), and -$6.6 million (Q4 2025), per Business Quant data.